Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins

Cell Reports

Volumn 13, Issue 3, 2015, Pages 524-532

  Wang, Wenqi ^a   Li, Nan ^a   Li, Xu ^a   Tran, My Kim ^a   Han, Xin ^a   Chen, Junjie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOMOTIN FAMILY PROTEIN; ONCOPROTEIN; PROTEIN; RNF 146; TANKYRASE; TANKYRASE 1; TANKYRASE INHIBITOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; YAP PROTEIN; 7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; AMOT PROTEIN, HUMAN; ENZYME INHIBITOR; FUSED HETEROCYCLIC RINGS; G007-LK; MEMBRANE PROTEIN; PHOSPHOPROTEIN; PROTEIN BINDING; RNF146 PROTEIN, HUMAN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SULFONE; TRIAZOLE DERIVATIVE; UBIQUITIN PROTEIN LIGASE; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CONTROLLED STUDY; ENZYME ACTIVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; HEK293 CELL LINE; HUMAN; MCF-7 CELL LINE; METABOLISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ENZYME INHIBITORS; HEK293 CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MCF-7 CELLS; MEMBRANE PROTEINS; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN STABILITY; PROTEOLYSIS; SULFONES; TANKYRASES; TRIAZOLES; UBIQUITIN-PROTEIN LIGASES;

EID: 84944679753     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.09.014     Document Type: Article

References (49)

1. Adler J.J., Johnson D.E., Heller B.L., Bringman L.R., Ranahan W.P., Conwell M.D., Sun Y., Hudmon A., Wells C.D. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. Proc. Natl. Acad. Sci. USA 2013, 110:17368-17373.
2. Camargo F.D., Gokhale S., Johnnidis J.B., Fu D., Bell G.W., Jaenisch R., Brummelkamp T.R. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 2007, 17:2054-2060.
3. Chan S.W., Lim C.J., Chong Y.F., Pobbati A.V., Huang C., Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J. Biol. Chem. 2011, 286:7018-7026.
4. Chan S.W., Lim C.J., Guo F., Tan I., Leung T., Hong W. Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation. J. Biol. Chem. 2013, 288:37296-37307.
5. Dai X., She P., Chi F., Feng Y., Liu H., Jin D., Zhao Y., Guo X., Jiang D., Guan K.L., et al. Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J. Biol. Chem. 2013, 288:34041-34051.
6. Debnath J., Muthuswamy S.K., Brugge J.S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268.
7. DeRan M., Yang J., Shen C.H., Peters E.C., Fitamant J., Chan P., Hsieh M., Zhu S., Asara J.M., Zheng B., et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep. 2014, 9:495-503.
8. Dong J., Feldmann G., Huang J., Wu S., Zhang N., Comerford S.A., Gayyed M.F., Anders R.A., Maitra A., Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130:1120-1133.
9. Guettler S., LaRose J., Petsalaki E., Gish G., Scotter A., Pawson T., Rottapel R., Sicheri F. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell 2011, 147:1340-1354.
10. Halder G., Johnson R.L. Hippo signaling: growth control and beyond. Development 2011, 138:9-22.
11. Harvey K.F., Zhang X., Thomas D.M. The Hippo pathway and human cancer. Nat. Rev. Cancer 2013, 13:246-257.
12. Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., Charlat O., Wiellette E., Zhang Y., Wiessner S., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
13. Huang J.M., Nagatomo I., Suzuki E., Mizuno T., Kumagai T., Berezov A., Zhang H., Karlan B., Greene M.I., Wang Q. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene 2013, 32:2220-2229.
14. Jiao S., Wang H., Shi Z., Dong A., Zhang W., Song X., He F., Wang Y., Zhang Z., Wang W., et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 2014, 25:166-180.
15. Kang H.S., Beak J.Y., Kim Y.S., Herbert R., Jetten A.M. Glis3 is associated with primary cilia and Wwtr1/TAZ and implicated in polycystic kidney disease. Mol. Cell. Biol. 2009, 29:2556-2569.
16. Kapoor A., Yao W., Ying H., Hua S., Liewen A., Wang Q., Zhong Y., Wu C.J., Sadanandam A., Hu B., et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 2014, 158:185-197.
17. Koontz L.M., Liu-Chittenden Y., Yin F., Zheng Y., Yu J., Huang B., Chen Q., Wu S., Pan D. The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev. Cell 2013, 25:388-401.
18. Kuratomi G., Komuro A., Goto K., Shinozaki M., Miyazawa K., Miyazono K., Imamura T. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem. J. 2005, 386:461-470.
19. Lamothe S.M., Zhang S. The serum- and glucocorticoid-inducible kinases SGK1 and SGK3 regulate hERG channel expression via ubiquitin ligase Nedd4-2 and GTPase Rab11. J. Biol. Chem. 2013, 288:15075-15084.
20. Lau T., Chan E., Callow M., Waaler J., Boggs J., Blake R.A., Magnuson S., Sambrone A., Schutten M., Firestein R., et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2013, 73:3132-3144.
21. Lei Q.Y., Zhang H., Zhao B., Zha Z.Y., Bai F., Pei X.H., Zhao S., Xiong Y., Guan K.L. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol. Cell. Biol. 2008, 28:2426-2436.
22. Levaot N., Voytyuk O., Dimitriou I., Sircoulomb F., Chandrakumar A., Deckert M., Krzyzanowski P.M., Scotter A., Gu S., Janmohamed S., et al. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell 2011, 147:1324-1339.
23. Li N., Zhang Y., Han X., Liang K., Wang J., Feng L., Wang W., Songyang Z., Lin C., Yang L., et al. Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth. Genes Dev. 2015, 29:157-170.
24. Lin L., Sabnis A.J., Chan E., Olivas V., Cade L., Pazarentzos E., Asthana S., Neel D., Yan J.J., Lu X., et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 2015, 47:250-256.
25. Liu X., Yang N., Figel S.A., Wilson K.E., Morrison C.D., Gelman I.H., Zhang J. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene 2013, 32:1266-1273.
26. Liu-Chittenden Y., Huang B., Shim J.S., Chen Q., Lee S.J., Anders R.A., Liu J.O., Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012, 26:1300-1305.
27. Makita R., Uchijima Y., Nishiyama K., Amano T., Chen Q., Takeuchi T., Mitani A., Nagase T., Yatomi Y., Aburatani H., et al. Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am. J. Physiol. Renal Physiol. 2008, 294:F542-F553.
28. Michaloglou C., Lehmann W., Martin T., Delaunay C., Hueber A., Barys L., Niu H., Billy E., Wartmann M., Ito M., et al. The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. PLoS ONE 2013, 8:e61916.
29. Miller E., Yang J., DeRan M., Wu C., Su A.I., Bonamy G.M., Liu J., Peters E.C., Wu X. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem. Biol. 2012, 19:955-962.
30. Mo J.S., Park H.W., Guan K.L. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014, 15:642-656.
31. Overholtzer M., Zhang J., Smolen G.A., Muir B., Li W., Sgroi D.C., Deng C.X., Brugge J.S., Haber D.A. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. USA 2006, 103:12405-12410.
32. Ozaki Y., Matsui H., Asou H., Nagamachi A., Aki D., Honda H., Yasunaga S., Takihara Y., Yamamoto T., Izumi S., et al. Poly-ADP ribosylation of Miki by tankyrase-1 promotes centrosome maturation. Mol. Cell 2012, 47:694-706.
33. Pan D. The hippo signaling pathway in development and cancer. Dev. Cell 2010, 19:491-505.
34. Paramasivam M., Sarkeshik A., Yates J.R., Fernandes M.J., McCollum D. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol. Biol. Cell 2011, 22:3725-3733.
35. Riffell J.L., Lord C.J., Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat. Rev. Drug Discov. 2012, 11:923-936.
36. Shao D.D., Xue W., Krall E.B., Bhutkar A., Piccioni F., Wang X., Schinzel A.C., Sood S., Rosenbluh J., Kim J.W., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014, 158:171-184.
37. Skouloudaki K., Walz G. YAP1 recruits c-Abl to protect angiomotin-like 1 from Nedd4-mediated degradation. PLoS ONE 2012, 7:e35735.
38. Smith S., Giriat I., Schmitt A., de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998, 282:1484-1487.
39. Waaler J., Machon O., Tumova L., Dinh H., Korinek V., Wilson S.R., Paulsen J.E., Pedersen N.M., Eide T.J., Machonova O., et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012, 72:2822-2832.
40. Wang W., Huang J., Chen J. Angiomotin-like proteins associate with and negatively regulate YAP1. J. Biol. Chem. 2011, 286:4364-4370.
41. Wang C., An J., Zhang P., Xu C., Gao K., Wu D., Wang D., Yu H., Liu J.O., Yu L. The Nedd4-like ubiquitin E3 ligases target angiomotin/p130 to ubiquitin-dependent degradation. Biochem. J. 2012, 444:279-289.
42. Wang W., Huang J., Wang X., Yuan J., Li X., Feng L., Park J.I., Chen J. PTPN14 is required for the density-dependent control of YAP1. Genes Dev. 2012, 26:1959-1971.
43. Yi C., Troutman S., Fera D., Stemmer-Rachamimov A., Avila J.L., Christian N., Persson N.L., Shimono A., Speicher D.W., Marmorstein R., et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 2011, 19:527-540.
44. Yu F.X., Zhao B., Panupinthu N., Jewell J.L., Lian I., Wang L.H., Zhao J., Yuan H., Tumaneng K., Li H., et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012, 150:780-791.
45. Zhang H., Liu C.Y., Zha Z.Y., Zhao B., Yao J., Zhao S., Xiong Y., Lei Q.Y., Guan K.L. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J. Biol. Chem. 2009, 284:13355-13362.
46. Zhang Y., Liu S., Mickanin C., Feng Y., Charlat O., Michaud G.A., Schirle M., Shi X., Hild M., Bauer A., et al. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat. Cell Biol. 2011, 13:623-629.
47. Zhang W., Gao Y., Li P., Shi Z., Guo T., Li F., Han X., Feng Y., Zheng C., Wang Z., et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014, 24:331-343.
48. Zhao B., Li L., Lei Q., Guan K.L. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010, 24:862-874.
49. Zhao B., Li L., Lu Q., Wang L.H., Liu C.Y., Lei Q., Guan K.L. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011, 25:51-63.